Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of peptide-based therapeutics for the treatment of obesity, metabolic dysfunction–associated steatohepatitis (MASH/NASH), and liver-related diseases. The company operates within the biotechnology and pharmaceutical research industry and does not currently market approved products, generating no commercial product revenue as of the latest public disclosures. Its primary value drivers are internally developed drug candidates advancing through clinical trials.
Altimmune’s core strategic positioning centers on novel dual-acting peptide therapies designed to address multiple metabolic and inflammatory pathways simultaneously. The company’s most advanced program, pemvidutide, targets both GLP‑1 and glucagon receptors, differentiating it from single‑mechanism incretin therapies. Altimmune was founded in 1997 (originally as Vaxin Inc.) and later merged with PharmAthene in 2017, adopting the Altimmune name and refocusing its pipeline toward metabolic and liver diseases following the wind-down of certain vaccine programs.
Business Operations
Altimmune operates as a single reportable operating segment focused on research and development. The company’s business model is centered on advancing proprietary therapeutic candidates through clinical development, with future revenue expected to be derived from regulatory approvals, commercialization, or strategic partnerships and licensing agreements. Operations are primarily domestic, with clinical trials conducted both in the United States and select international locations through contract research organizations.
The company’s pipeline is led by pemvidutide, a subcutaneously administered peptide in Phase 2 clinical development for obesity and MASH. Altimmune also maintains earlier-stage programs targeting liver diseases using its proprietary peptide engineering capabilities. The company does not operate manufacturing facilities and instead relies on third-party vendors for clinical trial materials, testing, and regulatory support.
Strategic Position & Investments
Altimmune’s strategic direction emphasizes capital-efficient clinical development of differentiated metabolic therapies with the potential to compete in large, underserved markets. The company has prioritized advancing pemvidutide through mid-stage clinical trials to demonstrate efficacy, safety, and differentiation relative to existing GLP‑1–based treatments. Management has stated that partnering or strategic transactions may be considered to support late-stage development or commercialization.
Historically, Altimmune has streamlined its portfolio by discontinuing non-core programs and reallocating resources toward metabolic disease indications. The company does not report ownership of significant operating subsidiaries and has not announced major acquisitions in recent years. Investment activity is primarily internal, focused on R&D expenditures, clinical trials, and intellectual property protection related to its peptide therapeutics platform.
Geographic Footprint
Altimmune is headquartered in Gaithersburg, Maryland, and its operations are primarily based in the United States. Corporate management, research oversight, and regulatory strategy are centralized at its U.S. headquarters. The company does not maintain significant physical operations outside the U.S.
International exposure is achieved through global clinical trial sites and collaborations with international contract research organizations. While Altimmune does not report material revenue or permanent offices outside North America, its clinical development activities provide it with a growing regulatory and operational footprint across North America and Europe in support of future global commercialization pathways.
Leadership & Governance
Altimmune is led by an executive team with experience in biopharmaceutical development, clinical research, and public company management. The leadership emphasizes disciplined capital allocation, data-driven clinical execution, and the development of differentiated therapies addressing unmet medical needs in metabolic and liver diseases.
Key executives include:
- William Enright – President and Chief Executive Officer
- Gregory Weaver – Chief Financial Officer
- Scott Harris, M.D. – Chief Medical Officer
- Robert Schottenstein – Chief Operating Officer
The company is governed by a board of directors with backgrounds in biotechnology, finance, and pharmaceutical development, providing oversight on strategy, risk management, and shareholder interests.